These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2096408)

  • 41. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
    Kuhs H; Folkerts H
    Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Haloperidol plasma levels and clinical response in paranoid schizophrenics.
    Linkowski P; Hubain P; von Frenckell R; Mendlewicz J
    Eur Arch Psychiatry Neurol Sci; 1984; 234(4):231-6. PubMed ID: 6526061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does the change of psychopathology during the placebo period predict the response to subsequent treatment with active medication.
    Libiger J; Czobor P; Volavka J
    Psychiatry Res; 1994 May; 52(2):107-14. PubMed ID: 7972567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Review of haloperidol blood level and clinical response: looking through the window.
    Volavka J; Cooper TB
    J Clin Psychopharmacol; 1987 Feb; 7(1):25-30. PubMed ID: 3546403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
    Aravagiri M; Marder SR; Van Putten T; Marshall BD
    J Chromatogr B Biomed Appl; 1994 Jun; 656(2):373-81. PubMed ID: 7987490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
    Yasui N; Kondo T; Otani K; Furukori H; Mihara K; Suzuki A; Kaneko S; Inoue Y
    J Clin Psychopharmacol; 1999 Apr; 19(2):149-54. PubMed ID: 10211916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
    Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
    Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up.
    Reyntigens AJ; Heykants JJ; Woestenborghs RJ; Gelders YG; Aerts TJ
    Int Pharmacopsychiatry; 1982; 17(4):238-46. PubMed ID: 7185768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of haloperidol plasma concentrations between twice-a-day and once-a-day dosing in Chinese schizophrenic patients.
    Lin SK; Chen CH; Chang WH
    J Formos Med Assoc; 1993 Sep; 92(9):832-4. PubMed ID: 7904867
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study.
    Haas S; Beckmann H
    Pharmacopsychiatria; 1982 Mar; 15(2):70-4. PubMed ID: 7043498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 57. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.
    Möller HJ; Boyer P; Fleurot O; Rein W
    Psychopharmacology (Berl); 1997 Aug; 132(4):396-401. PubMed ID: 9298518
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.
    Ulrich S; Wurthmann C; Brosz M; Meyer FP
    Clin Pharmacokinet; 1998 Mar; 34(3):227-63. PubMed ID: 9533984
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.